|1.||Akslen, Lars A: 8 articles (12/2007 - 10/2003)|
|2.||Ordóñez, Nelson G: 7 articles (07/2014 - 08/2003)|
|3.||Foulkes, William D: 6 articles (10/2008 - 10/2003)|
|4.||Weissferdt, Annikka: 5 articles (03/2015 - 07/2011)|
|5.||Moran, Cesar A: 5 articles (03/2015 - 07/2011)|
|6.||Wang, Xiao-Jing: 5 articles (12/2014 - 04/2004)|
|7.||Perou, Charles M: 5 articles (03/2008 - 12/2002)|
|8.||Stefansson, Ingunn M: 5 articles (03/2006 - 10/2003)|
|9.||Sartorius, Carol A: 4 articles (11/2015 - 07/2011)|
|10.||Koo, Ja Seung: 4 articles (02/2015 - 01/2010)|
02/01/2014 - "Although there was no significant difference in the frequency of expression of cytokeratin 5/6, p63, HER2, GATA3, and mammaglobin in cutaneous apocrine carcinoma versus mammary apocrine carcinoma, strong and diffuse cytokeratin 5/6 and/or mammaglobin expression were seen only in cutaneous apocrine carcinoma. "
11/01/2011 - "Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma."
01/01/2010 - "Immunohistochemical identification of basal-like carcinomas is hindered with a fact, that on microarray level not all of them express basal-type cytokeratin 5/6, 14 and 17. "
09/01/2008 - "Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively. "
08/01/2007 - "Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6."
01/01/2006 - "To study the role of E2F3 in tumor development, we established a transgenic mouse model expressing E2F3a in a number of epithelial tissues via a keratin 5 (K5) promoter. "
11/01/2015 - "Cytokeratin 5 expression correlated with ER positivity (38 of 42 CK5 tumors were also ER). "
03/01/2013 - "Antizyme (AZ) is a multifunctional negative regulator of cellular polyamine levels, and here, we evaluate the susceptibility of keratin 5 (K5)-AZ transgenic mice to tumor models that combine chemical carcinogenesis with dietary and genetic risk factors known to influence human susceptibility to UADT cancer and promote UADT carcinogenesis in mice. "
10/01/2012 - "We have previously described that in some ER(+) tumors, the resistant cells express cytokeratin 5 (CK5), a putative marker of breast stem and progenitor cells. "
09/01/2012 - "Nuclear immunoreactivity for WT1 or keratin 5 positivity was not detected in myofibroblastic tumors. "
11/01/2012 - "In addition, anterior gradient homolog 2 and MUC5AC are useful positive markers of adenocarcinoma in the setting of absent or diminished p63 and cytokeratin 5/6 staining."
08/01/2007 - "Neoplastic basal cells and less-differentiated adenocarcinoma cells, which were identifiable by immunolabelling for cytokeratin 5 (CK5) and CK18, were considered to be pluripotential. "
12/01/2009 - "The purpose of this study was to determine whether SOX2 is differentially expressed in squamous cell carcinomas versus adenocarcinomas of the esophagus and rectum/anal canal and to compare its expression to p63, cytokeratin 5/6, and CDX2. "
08/01/1997 - "Previous studies using frozen material have suggested that cytokeratin 5 is expressed by pleural mesothelioma but not by adenocarcinoma. "
11/01/2012 - "Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping."
08/01/2008 - "Cytokeratin 5/6 staining was also present in 33/34 (97%) of mesothelioma cases. "
06/01/2002 - "Cytokeratin 5/6 antibody, which recently became commercially available, has been found useful in the diagnosis of mesothelioma. "
05/01/2001 - "These results suggest that cytokeratin 5/6 is neither a sensitive nor specific stain for the diagnosis of mesothelioma in cytology material. "
08/01/1997 - "Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma."
01/01/1989 - "Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. "
|5.||Noninfiltrating Intraductal Carcinoma (DCIS)
07/01/2006 - "Recent studies have demonstrated that immunohistochemical staining for cytokeratin 5/6 can distinguish UDH from conventional forms of ductal carcinoma in situ. "
05/01/2013 - "The immunohistochemical expression of cytokeratin 5/6 by ductal carcinoma in situ epithelial cells may provide clinically useful information regarding the risk of progression to invasive disease."
05/01/2013 - "In the low-grade ductal carcinoma in situ subgroup, only cytokeratin 5/6 expression exhibited a negative association with the probability of invasion. "
02/01/2007 - "A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. "
07/01/2006 - "We tested the hypothesis that the results of staining for cytokeratin 5/6 can distinguish UDH from the solid papillary variant of ductal carcinoma in situ. "
|5.||Keratin-7 (Cytokeratin 7)
|7.||adjuvant P40 (P 40)
|8.||Keratin-14 (Keratin 14)
|10.||Mucin-1 (CA 15-3 Antigen)
|1.||Drug Therapy (Chemotherapy)